Clinical Trial Update: Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing a fixed-dose combination of nifedipine and candesartan to the loose combination of the two drugs, administered in the f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Candesartan (candesartan)
• Nifedipine (nifedipine)

Snippet

Sponsor: Bayer | Conditions: Hypertension, Essential | Phase 1 | Status: COMPLETED